downside of IVIG therapy is its high price. Therefore, clinicians should balance efficiency versus cost in deciding whether or not to treat certain conditions with IVIG.
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Intravenous immunoglobulin (IVIG) is a safe preparation made from sterilized purified human plasma from thousands of healthy donors per batch. Therefore, IVIG most likely contains the entire wide spectrum of variable regions present in normal plasma. [1] [2] [3] IVIG contains more than 95% intact immunoglobulin G (IgG) molecules, with traces of immunoglobulin A (IgA) (<2.5%) and immunoglobulin M (IgM) (negligible). The IgG subclasses distribution corresponds to that of normal human plasma. [1] [2] [3] [4] Petaglobin, an IVIG preparation, is IgM enriched. 5 The therapeutic immunomodulatory effect of IVIG lies within its content. A standard IVIG preparation contains natural antibodies that are more polyreactive than are immune antibodies, including IgG antibodies against endogenous antibodies. These IgG antibodies are known to be anti-idiotypic and are able to neutralize and immunomodulate autoantibodies. 3, 4 IVIG also contains natural autoantibodies against DNA, phospholipids, gangliosides, and glycolipid-sulfatide, 6, 7 as well as IgG antibodies against exogenous antigens (bacteria, viruses, etc.), F(ab′) 2 fragments of IgG, immunomodulating peptides (CD4, CD8, CD95, etc.), and various cytokines (interleukin [IL]-2, IL-4, IL-10, transforming growth factor-β, etc.). 4, [8] [9] [10] [11] Importantly, the natural autoantibodies (i.e., antiphospholipid and anti-DNA autoantibodies) within IVIG are nonpathogenic in vivo, most likely because of low affinity toward the autoantigenic target. 6 IVIG, when administered properly to a selected patient population, was shown to be an effective treatment in autoimmune and cancer diseases, as well as for recurrent pregnancy loss, with side effects that are mostly mild and transient. 5, 12 
THE HISTORY OF IVIG
The origin of IVIG use dates back to 1930 at Boston City Hospital, where a clinical experiment was conducted from 1919 to 1929 by M. Finland, in which equine serum was given to treat pneumococcal pneumonia. Although the treatment had side effects, namely, acute febrile reactions and serum sickness, it seemed that the therapy improved survival from pneumonia. 13 In 1940, Edwin J. Cohn from Harvard University used human albumin from 19 donors to treat combat shock in soldiers wounded on the battlefield in World War II. In 1941, Cohn developed a process to produce human albumin (using ethanol as a precipitant) and recognized fractions containing gamma globulin, as well as prothrombin, lipoproteins, and other proteins. 14 Cohn acknowledged the importance of the globulins as a potent substitute "for convalescent serum." Cohn's collaborator, Oncley, separated (by molecular weight) the gamma globulins from prothrombin, plasminogen, and isohemagglutinins. 15 After World War II, in the mid-1940s, injections of separated gamma globu-lins became common as a substitute for earlier placental extract preparations of globulin, mainly to prevent or attenuate viral diseases. 16 The first use of gamma globulin that was not related to infections or immunodeficiencies was attempted in the 1940s by Diamond, who worked with Cohn's fractions and tried to develop an anti-Rh globulin to prevent erythroblastosis fetalis. 14 However, the use of intravenous administration of gamma globulins was discontinued after Janeway 17 found it to be the frequent cause of immediate vasomotor reactions, chills, and fever. A significant case report was detailed in 1952 when an immunodeficiency patient was successfully treated with gamma globulin injections. 18 A valuable contribution to the use of IVIG as a treatment for autoimmune diseases was made by Imbach et al. , who reported in 1981 on its beneficial effect in children with chronic thrombocytopenia and immunodeficiency. Imbach was the first to observe that the IVIG treatment improved the condition of the children with immunodeficiency and ameliorated the thrombocytopenia. Imbach immediately implemented this treatment for idiopathic thrombocytopenia purpura (ITP), indicating the efficacy of IVIG in other autoimmune conditions. 19 To date, IVIG has been given for a variety of autoimmune, inflammatory, and neurologic diseases and many other conditions. In some diseases, a beneficial effect was proved, such as in ITP and Kawasaki syndrome, whereas in others it is still debatable, for example, multiple sclerosis. 16, 20 
IVIG FOR IMMUNODEFICIENCY
The original purpose for using gamma globulin injections in the early to mid1940s was mainly to prevent or attenuate viral diseases. Back then, immunodeficiency diseases had not yet been discovered. 16 As summarized by Berger, 16 it was Bruton who made a seminal contribution. In 1952, Bruton reported an 8-year-old boy who had recurrent infections associated with agammaglobulinemia. The boy was treated monthly with subcutaneous injections of gamma globulins, and consequently sepsis and serious infections were healed.
In the 1950s and early 1960s, the Medical Research Council in England conducted a clinical trial comprising 176 patients with primary hypogammaglobulinemia who were treated with intramuscular injections of 25 or 50 mg/kg/week gamma globulin. The high-dose treatment was more effective in reducing C-reactive protein levels, febrile episodes, number of death reports, pneumoniae, and otitis media. The Medical Research Council approved the high-dose IVIG only for patients in whom the low-dose treatment failed to prevent severe infections. 21 Today, IVIG is widely used in immunodeficiencies; that is, IVIG is given as prophylaxis against severe infections or as an adjunctive measure for sepsis. Treatment with IVIG against severe infections led to a reduction in infection occurrence, infection-related mortality, and duration of hospitalization. Treatment of sepsis with IVIG led to a significant reduction in mortality from sepsis and septic shock, as reported in the Cochrane database. 22, 23 Another important use of IVIG is for allogeneic stem cell transplantation. Patients undergoing transplantations are given immunosuppressive treatment to minimize the probability of organ rejection. The value of IVIG in transplantations lies in both preventing infections and reducing the occurrence and severity of acute graft-versus-host disease. 22 In 1982, the U.S. Food and Drug Administration approved the use of IVIG as part of the treatment regimen for chemoblasted recipients of allogeneic bone marrow stem cell transplantation. 22 The experience gained with IVIG in bone marrow transplantation has been controversial. A beneficial effect of IVIG in bone marrow transplantation has yet to be established, although it is clear that IVIG is efficient against some viral (cytomegalovirus, herpes virus, Epstein-Barr virus, parvovirus B19, and others) and bacterial infections (Mycoplasma pneumoniae, Chlamydia pneumoniae, Helicobacter pylori, etc.). 24 
IVIG FOR AUTOIMMUNE DISEASES
The first major contribution to the use of IVIG in autoimmunity was made by Imbach in 1981. Using the Swiss Red Cross IV preparation to treat children with Wiskott-Aldrich syndrome and thrombocytopenia, he noticed an improvement in both their immune deficiency and their thrombocytopenia. Thereafter, Imbach used IVIG to treat children with ITP who did not have an immune deficiency and were refractory to conventional treatments. The idea was that IVIG might interfere with the immune responses of the platelet-targeted autoantibody. A drastic increase in platelet count was observed and all the children were cured. 19 In 1990, the National Institutes of Health consensus approved the use of IVIG in ITP. 25 In the early 1980s, IVIG was used successfully to treat hemophilic patients, as well as patients with Kawasaki syndrome. 26, 27 Because Kawasaki syndrome is an inflammatory autoimmune disease, the findings led to IVIG being implemented as a treatment for inflammatory conditions, independent of an autoimmune background. During the 1980s, beneficial effects of IVIG were observed when it was given as a treatment for autoimmune neurological diseases, such as myasthenia gravis, 28, 29 Guillain-Barré syndrome, 30 and chronic idiopathic demyelinating polyneuropathy. 31 From the 1990s, IVIG was also shown to be beneficial in polymyositis, dermatomyositis, 32, 33 and stiff-person syndrome. 34 Today, the therapeutic effects of IVIG have been well established for several autoimmune diseases, including ITP, Guillain-Barré syndrome, Kawasaki disease, polymyositis, and dermatomyositis. 20 Moreover, there are indications for the efficacy of IVIG in other autoimmune conditions as well (TABLES 1A-1D). Several beneficial effects of IVIG have been reported with regard to systemic lupus erythematosus (SLE), 127 vasculitides, 104 factor VIII inhibitor, 35 recurrent pregnancy loss as a result of antiphospholipid syndrome (APS), 36, 37 fibrosis, 21, 132, 133 heparin-induced thrombocytopenia, 153, 154 and others. 133, 136 TABLE 1A presents diseases in which the therapeutic effect of IVIG has been established in controlled trials. 3 
Mechanisms of Action of IVIG in Autoimmunity
IVIG exerts its immunomodulatory effects in a multiple mechanistic way that is not fully defined. Some of the mechanisms of action of IVIG involve (1) Fc receptor A. The treatment had no effect on survival, the incidence of obliterative bronchiolitis, severity of airflow obstruction, or the incidence or mortality of chronic GVHD.
A. 103 
A. 136
Insulin-dependent diabetes mellitus A. 10 children were treated with 2 g/kg IVIG and subsequently, after 15 days, every month for 6 months, and continued to receive Insulin. The treatment success for the long-term was similar to that of the control group.
A. Serum post-prandial C-peptide level was significantly higher after 6 months in IVIG recipients. This difference was no longer significant at 18 and 24 months. Insulin requirement in the IVIG group was significantly lower at 6 months. This difference was no longer significant at 12 months.
A. 137 Toxic epidermal necrolysis syndrome A. 16 patients were treated with 0.5-0.9 g/kg/day IVIG for 3-5 days. The treatment success was similar to that of the control group. B. 10 patients were treated with IVIG. The treatment succeeded in all (100%).
A. There were no significant differences with respect to length of stay, duration of mechanical ventilation, severity of systemic inflammatory response syndrome, and multiple organ dysfunction syndrome, the incidence of sepsis or mortality rate. Although there may have been a trend towards less severe wound progression in IVIG recipients, it was not associated with any substantial improvement in the patients' outcome. B. The progression rapidly reversed and the outcome was favorable. Felty's syndrome A. 5 patients were treated with high-dose IVIG. The treatment did not succeed in any of the patients.
A. The neutrophil count did not change. A. 160
Severe steroiddependent atopic dermatitis A. 3 patients, who had steroid-related side effects, were treated monthly with 2 g/ kg IVIG, and continued to receive steroids. The treatment succeeded in all (100%). B. 6 treatment-resistant patients were treated monthly with 2 g/kg IVIG for 6 cycles. The treatment succeeded in 4 (67%). C. Combined case reports: 32 treatmentresistant patients were treated with high-dose IVIG. The treatment succeeded in 20 (61%).
A. An improvement in skin scores was observed and the steroid dose was reduced. Total IgE decreased in 1/3 patients. B. Major improvements in skin scores and a significant overall reduction were observed. CD4+ T cell titers decreased following IVIG, and recovered by the next cycle. T cell CD69 expression decreased to 60% of baseline values. Reductions in interferon gamma (IFN) and TNFα were non-significant. C. Adults appeared less likely to respond than children and the duration of response was also more prolonged in children. Adjunctive therapy in adults was more effective than monotherapy, whereas monotherapy was effective in children.
A. 161 B. 162 C. 163 A. Crohn's disease A. A patient was successfully treated with IVIG, after the disease could not be controlled with conventional antiinflammatory therapy. B. A patient was successfully treated with IVIG, after earlier treatment with various therapeutic regimens had been unsuccessful. C. 3 medically refractory patients, who were reluctant to receive immunosuppressive therapy or have surgical intervention, were treated with 2 g/kg IVIG followed by a maintenance phase: 0.2-0.5 g/kg every 2 weeks for 12 or 24 weeks. Tapering of systemic corticosteroid therapy was attempted, whereas other medications for idiopathic colitis were continued. The treatment succeeded in all (100%).
A. Her condition improved markedly, CD8 T cell levels returned to normal and IgM decreased. B. A complete remission was achieved.
During the next 2 relapses the same prompt positive response was obtained, although in the third the dose of IVIG had to be doubled. C. Statistically significant reductions were achieved in the colitis activity score and in daily prednisone dose.
A. 164 B. 165 C. 166
Hemolytic uremic syndrome (HUS)
A. A refractory patient, with a 2 year history of metastatic carcinoid tumor, underwent a multi-visceral transplant and received induction immunosuppression with humanized anti-CD52 panlymphocytic monoclonal antibody. Her maintenance immunosuppression consisted of steroids and tacrolimus. She developed anuric acute renal failure after the transplant, and was unsuccessfully treated with plasmapheresis, platelet transfusion, and discontinuation of tacrolimus. Subsequently, she was successfully treated with plasmapheresis and 20 g bolus IVIG, followed by 10 g/kg IVIG for 5 days, and received red blood cell transfusions. B. A patient, who underwent combined liver-kidney transplantation for hepatorenal polycystic disease, was initially unsuccessfully treated with withdrawal of cyclosporine, introduction of low-dose tacrolimus, and administration of fresh frozen plasma (FFP) transfusion and heparin. Subsequently the FFP treatment was replaced by plasmapheresis, followed by 0.4 mg/kg/day IVIG, and that treatment succeeded. C. 9 children with acute typical post-diarrhea hemolytic uremic syndrome were treated with IVIG. The treatment succeeded in 1 (11%).
A. Platelet count rose promptly and serum lactate dehydrogenase hormone (LDH) decreased. Four weeks later she was discharged home with normal renal function on rapamycin and steroids without recurrence of HUS. She continues to do well 9 months post-transplant. B. Rapid improvements in renal function, platelet count, and hemolytic anemia were observed. C. One child demonstrated both an increase in platelet count and a decrease in white blood cell (WBC) count within 24 hours of receiving the first dose of IVIG, but there were no significant differences found in 8/9 of the treated children in the duration of hemorrhagic colitis, thrombocytopenia, elevation of the WBC, anuria, dialysis, hospitalization, or the presence of a central nervous system complication or pancreatitis.
A. 167 B. 168 C. 169 Behcet's disease A. 4 patients (6 eyes) refractory to steroids and cyclosporin A were treated with 0.4 g/kg/day IVIG for one year. The treatment succeeded in 100% of the eyes (6/6).
A. IVIG brought the acute inflammation under control and preserved the remission for a period of at least 1 year. In patient 1, the inflammatory process improved and resolved to the degree of no cells and +1 flare in 10 days. After 3 months of treatment the right eye underwent cataract surgery, after which the protocol was continued. During 1 year of treatment the eye remained in remission, with 6/10 vision. In patient 2, ocular inflammation improved in 5 days and full resolution was noted in 10 days. Over 1 year on the treatment, and an additional year follow-up after completion of treatment, vitreal remission was retained, with 6/6 vision in each eye. In patient 3, after 3 weeks of treatment the eye improved. After 6 weeks, no sign of active inflammation, with visual acuity of 6/6, was achieved, and the eye was kept in remission for up to 1 year. In patient 4, After 5 weeks of treatment, the inflammation abated and visual acuity improved to 6/7 in the right eye and 6/9 in the left eye. After 6 months of stabilization, the patient was lost to follow-up and treatment. Three months later she returned with a relapse, and was put back on IVIG therapy. The inflammation abated in 2 weeks, with stabilization. There were no recurrences in the 1 year follow up.
A. 170 1, 38, 39 ; and (5) neutralization of toxins that trigger autoantibody production. 40 The primary mechanism of action of IVIG in some autoantibody-mediated cytopenias, like ITP, is considered to be a blockade of macrophage Fc receptors. [41] [42] [43] Because Fc receptor blockade may also inhibit antibody-dependent cell-mediated cytotoxicity, it can explain the protective effect of IVIG against demyelination in inflammatory neurological diseases. 4 IVIG exerts its anti-inflammatory activity in several ways in some autoimmune inflammatory diseases. In Kawasaki disease, IVIG is considered to (1) decrease proinflammatory cytokines levels, such as IL-1 44 ; (2) increase plasma levels of IL-1 receptor antagonist 45 ; and (3) neutralize the staphylococcal toxin by blocking blastic T cell apoptosis. 46, 47 In dermatomyositis, IVIG is assumed to prevent the activated components C3b and C4b from being deposited on target surfaces by binding them, thereby inhibiting the generation of membrane attack complexes (C5b-C9) and subsequent complement-mediated tissue damage. 48 The anti-inflammatory effect of IVIG in Guillain-Barré syndrome is by reduction of IL-1 levels. 49 The mechanism of action of IVIG in toxic epidermal necrolysis is via blocking Fas-mediated keratinocyte death by inhibiting Fas-Fas ligand interactions. 151 IVIG modulates hemolytic uremic syndrome patients by neutralizing antibodies against toxins (Shiga toxin and SLT-1 toxin). 50 IVIG contains high levels of anti-idiotypic antibodies that are able to bind and neutralize pathogenic autoantibodies in several autoimmune diseases, for example, (1) acquired hemophilia, in which IVIG neutralizes autoantibodies against factor VIII 51 ; (2) vasculitides, in which IVIG neutralizes autoantibodies against antineutrophil cytoplasmic autoantibodies 52 ; (3) SLE, in which IVIG neutralizes autoantibodies against DNA 53 ; (4) ITP, in which IVIG neutralizes autoantibodies against the platelets' glycoprotein 54 ; and (5) APS, in which IVIG neutralizes autoantibodies against phospholipids, for example, anticardiolipin. 53 Note that the antiidiotypic immunomodulatory effects are extended also to T cells. 55, 56 Conclusion IVIG is an efficient and safe therapy for many autoimmune diseases. The beneficial immunomodulatory effects of IVIG have been established in only a few autoimmune diseases. IVIG provides a good solution for patients with autoimmune diseases refractory to conventional therapy.
IVIG FOR CANCER
Patients with hematological malignancies, such as leukemia, are exposed to recurrent infections. Therefore, IVIG can reduce the frequency of infections in these patients. IVIG might also be an appropriate treatment for cancer patients undergoing chemotherapy. 5 Cancer and autoimmune diseases share several significant features: (1) an autoimmune disease is often detected in cancer patients, and vice versa, for example, Eaton-Lambert's syndrome in patients with small cell carcinoma of the lung, or thy-moma in patients with myasthenia gravis [57] [58] [59] ; (2) the variety of autoantibodies seen in cancer patients, such as anti-DNA, RNP, and Sm antibodies in patients with lymphoma 60, 61 ; (3) a possible common genetic background; (4) a common immunodeficiency course, such as IgA deficiency 38, 57, 62 ; (5) etiology due to common viruses (i.e., Epstein-Barr virus and cytomegalovirus) and bacteria (e.g., Helicobacter pylori) 38, 57, 62 ; and (6) common treatment, such as immunosuppressive and cytotoxic drugs. 63 Given the bidirectional relationship between cancer and autoimmunity and the fact that cancer patients are often immunosuppressed, it was logical to treat cancer patients with IVIG. The clinical experience with IVIG in cancer patients is limited, but beneficial effects have been described in several reports. 
Mechanisms of Action of IVIG in Cancer
Similar to the effects of IVIG in autoimmune diseases, IVIG exerts its antimetastatic effects in diverse, complicated mechanisms that are not fully defined. Some of the antimetastatic effects of IVIG are (1) elevation of IL-12 secretion and a subsequent enhancement of natural killer cell activity 64 ; (2) inhibition of matrix metalloproteinase-9 activity 65 ; and (3) inhibition of some malignant cell line growth, including lymphoma and colon carcinoma cell lines, by increasing both the expression of proapoptotic genes and Fas expression. 63 
Conclusion
IVIG significantly reduces metastases in a broad spectrum of cancer cell lines, does not affect normal cell lines (bone marrow progenitors), and is considered an effective and safe agent. It can be a potent anticancer drug, suitable for cancer patients with disease in early and advanced stages. 63, [66] [67] [68] 177 
IVIG FOR RECURRENT PREGNANCY LOSS
There are several reasons why recurrent pregnancy loss (RPL) occurs. One of the causes of RPL is an autoimmune disease, such as APS. Frequently, however, the reason cannot be found and these cases are referred to as spontaneous or idiopathic RPL.
RPL Caused by an Autoimmune Disease
One of the diseases associated with RPL is antiphospholipid syndrome. APS is an autoimmune disease in which RPL might occur as a result of several mechanisms, such as autoantibodies against placental membrane phospholipids, increased platelet aggregation, decreased endogenous anticoagulant activity, and complement activation. 12, 69 Interestingly, it was found that women with a history of RPL have higher levels of autoantibodies to a variety of cell and tissue components, especially IVIG treatment was given for the polymyositis, and the Kaposi's sarcoma regressed abruptly.
173
Chronic lymphocytic leukemia 5 patients, in clinical stage III and IV, were treated with a 5 day infusion of high-dose IVIG for either autoimmune hemolytic anemia or ITP, or by a dose of IgG every 3-4 weeks for prevention and control of infections associated with hypogammaglobulinemia. The treatment succeeded in all (100%).
The IgG treatment succeeded for the autoimmune hemolytic anemia when combined with steroids, chemotherapy, plasmapheresis, and splenectomy, and for the ITP when combined with chemotherapy. Lymphocytopenic effects were observed in all patients during IVIG for 5 days. Furthermore, the maintenance IgG given every 3 weeks controlled both infections and lymphocyte counts with the chemotherapy. Changing the schedule to every 4 weeks resulted in poor control of the lymphocyte counts with chemotherapy. The lymphocytopenic effect suggests immunomodulating effects of IgG, which may alter the response of chronic lymphocytic leukemia cells to chemotherapy.
anticardiolipin antibodies, but also anticoagulant, antithyroglobulin, antiphosphatidylserine, antiphosphatidylethanolamine, antiphosphatidylinositol, antiphosphatidylglycerol, and antiphosphatidic acid. 12, 20, 70, 71 Moreover, an inverse correlation has been reported between anticardiolipin antibodies levels and the probability of a successful pregnancy. 12 Although RPL includes several autoimmune characteristics and might occur as a result of an autoimmune disease that has yet to be found, it is still unclear whether the presence of the above-mentioned autoantibodies is the cause or the result of the reproductive failure, or an artifact of prior reproductive losses. 12 Improved responses to IVIG have been seen in RPL that occur as a result of an autoimmune background (such as APS in TABLE 1B). For example, IVIG therapy (with or without aspirin/heparin) for APS patients with RPL has led to successful pregnancy outcomes. 36, 37 Moreover, IVIG was also effective in in vitro fertilization for antibody-positive APS patients. 70 
Idiopathic RPL
Encouraging responses to IVIG have been seen for spontaneous RPL as well. 72 Several trials and series testing the therapeutic effect of IVIG in idiopathic RPL have been reported. 
Mechanisms of Action of IVIG in RPL
IVIG is believed to exert its immunomodulatory effects via several mechanisms of action that cooperate in different combinations to achieve a synergistic effect in RPL. The mechanisms of action include the following: (1) anti-idiotypic antibodies neutralize cytotoxic antibodies and thereby prevent them from binding to the fetoplacental unit 73 ; (2) downregulation of natural killer cell activity 73 ; and (3) polarization of Th1/Th2 ratio from Th1 (hostile endometrial environment) toward Th2 (trophoblast-friendly environment) by cytokine immunomodulation. 74, 75 In Conclusion
The reports of IVIG as a treatment for RPL are encouraging, but the efficacy of IVIG has yet to be established. 12, 72 Better results can be expected when a population of women is selected with a higher probability to respond to IVIG. In the meantime, one should not exclude IVIG as a potent therapy for RPL. 10 women, with a history of 3-5 spontaneous abortions, were treated monthly with 0.4 g/kg IVIG, beginning in the 5 th -6 th week of gestation, until the 28 th week of gestation in 5-, 3-and 1-day protocols. In 2/10 women therapy followed active immunotherapy with paternal lymphocytes. The treatment succeeded in 8 (80%).
Healthy infants were delivered, 3 preterm.
177
26 women with secondary recurrent abortions and a history of at least 4 unexplained abortions were treated with 0.8 g/kg IVIG, beginning as soon as the pregnancy test was positive, until the 20 th week of gestation, and 1 g/kg IVIG was given from gestational weeks 20-26. The treatment succeeded in 15 (58%).
Successful outcomes, in which the pregnancy progressed at least until the 26 th gestational week.
178
29 women, experiencing 2 or more consecutive spontaneous abortions, were treated monthly with 0.5 g/kg IVIG. The treatment succeeded in 18 (62%).
Live infants were delivered.
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72 women with a history of 5 or more abortions were treated with 0.4 g/kg IVIG in one day in the follicular phase of a cycle in which pregnancy was planned. A booster dose was administered when pregnancy was diagnosed. The treatment succeeded in 35 (49%).
Live infants were delivered, or the previous stage of abortion was passed.
180
12 women, with a history of at least 5 abortions, were treated with 0.4 g/kg IVIG, in the follicular phase of a cycle in which pregnancy was planned. A booster dose was administered as soon as pregnancy was diagnosed. Repeat infusions were given to women who had second-trimester losses. One woman received a third dose in the 33 rd week, due to growth retardation. The treatment succeeded in 5 (42%).
SIDE EFFECTS OF IVIG
When patients are well selected and when IVIG is given properly, side effects are rarely encountered (occurring in 10-30% of patients). When they do occur, they are mainly mild and transient. 2, 5, 72 Mild side effects include fatigue, fever, chills, myalgia, and headache. Possible serious side effects (very rare) are myocardial infarction, renal failure, alopecia, aseptic meningitis, and retinal necrosis. 2, 4, 5, 72 Side effects depend, among other factors, on the patient's age, the dose of IVIG, and the infusion rate. 5 To minimize the side effects, it is recommended that IVIG be administered in a dose not higher than 0.4 g/kg body weight in a 5-day schedule for 1 month (because the half-life of IgG is 3 weeks, except for IgG3, which has a half-life of 1 week). 20, 76 It is also recommended to administer IVIG in low-rate infusions, especially in patients with a compromised cardiovascular system or congestive heart failure, to avoid rapid fluid overload. 4, 72 Another important way to minimize IVIG side effects is to carefully select the patients receiving the therapy. For example, anaphylactic shock may occur in IgA-deficient patients after IVIG therapy; therefore, it is important to identify these patients to give them an IVIG preparation that is IgA-free. Patients with a history of side effects in general have a higher probability of developing adverse reactions to IVIG. These patients could be treated with corticosteroids intravenously half an hour before the administration of IVIG. 12 Additional risk factors to consider before administering IVIG include serum viscosity and prior thromboembolic events, tendency for migraines, and history of a renal disease or volume depletion in older patients. 4 Acute renal failure was reported to occur mainly when a sucrose-containing IVIG preparation was administered. Today, however, IVIG preparations no longer contain sucrose. 77, 78 
COST OF IVIG
IVIG is an expensive therapy, costing close to U.S. $3,000 for one course of 2 g/ kg IVIG for a patient weighing 70 kg. 79 The price range depends on several factors, such as where IVIG is administered (hospital, outpatient clinic, or home infusion program) and the number of days IVIG is being administered (2-5 days). 4 
CONCLUSION
IVIG is currently being used to treat several autoimmune diseases. Cancer and autoimmunity diseases share several characteristics. RPL could occur from an autoimmune disease or from an unknown cause. Generally, in RPL there are few autoimmune factors. Therefore, both cancer and RPL represent potent target diseases for IVIG therapy. Beneficial effects have been observed in a variety of autoimmune diseases, cancerous diseases, and RPL conditions (TABLES 1-3) . The mechanisms of action of IVIG are diverse and not fully elucidated. IVIG clearly has the ability to neutralize pathogenic autoantibodies, modulate the immune system, and inhibit metastatic spread. IVIG is a safe product if given properly and to selected patients.
The only disadvantage of IVIG is its high cost. Therefore, clinicians should balance the cost of IVIG therapy against symptom amelioration and quality of life, minus costs of conventional therapy, decreased complications, fewer hospital admissions, and time off from work. 1 IVIG can affect every component of the immune system. It should be considered in immune-mediated diseases as a treatment for patients whose disease is refractory to conventional therapies.
Important steps for the future include: (1) the generation of specific-IVIG (sIVIG), an immunoglobulin preparation consisting of anti-idiotypic antibodies against specific antibodies, purified from an IVIG preparation by affinity chromatography 39 ; and (2) the production of less expensive alternatives for IVIG, such as a synthetic preparation.
